Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda’s Global Ambitions Focus On Crohn’s, Cancer – And Churn

Executive Summary

Three product launches in U.S. last year, including Entyvio, showcase its expansion strategy, but first non-Japanese CEO could be biggest shift for firm.

You may also be interested in...



Velcade Patent Ruling Puts More Pressure On Ixazomib Candidate

District court finds formulation patent covering Takeda’s top drug is obvious in light of prior art, opening product up to generic competition in 2017.

European Biotech Is “Hot” Again, But Needs Nurturing For Further Growth

European biotech executives, entrepreneurs and investors are much more optimistic today about the sector’s growth prospects than just a few years ago – that’s despite lingering negatives like the region’s small number of mid-sized companies, a lack of investors willing to finance beyond seed and Series A rounds, and the relative dearth of executive talent.

Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch

Takeda’s beleaguered Nesina (alogliptin) becomes the fourth DPP-4 inhibitor approved by FDA for diabetes; it remains to be seen whether the drug can find its place in a highly competitive space that continues to be controlled by Merck’s first-to-market blockbuster Januvia.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel